STOCKSCOPE

BlueScope Steel (ASX: BSL) Lifts First-Half Earnings Outlook to $1.1 Billion as US Steel Margins Strengthen

Alison Elzayed

Alison Elzayed

Business & Finance Writer | StockScope

Published:26 Oct 2026
BlueScope Steel (ASX: BSL) Lifts First-Half Earnings Outlook to $1.1 Billion as US Steel Margins Strengthen

BlueScope Steel’s first-half earnings are now expected to reach approximately $1.1 billion, a substantial upgrade that highlights the earning power of its North American operations when steel markets improve. The key question for investors is whether this performance signals a more durable improvement in profitability or another peak in a cyclical industry.

Key numbers

  • $1.1 billion: Expected underlying EBIT for the first half of FY2027, up from previous guidance of $860 million to $960 million.
  • About $810 per tonne: Steel spread assumption underpinning stronger North Star earnings, compared with the previous $750 per tonne assumption.
  • $1.27 billion: Underlying EBIT reported for FY2026.
  • $802 million: Reported net profit after tax in FY2026, up 857% on the previous financial year.
  • $14.2 billion: Approximate market capitalisation following the latest share-price movement.

The latest development

BlueScope’s upgraded guidance reflects stronger-than-expected performance across North America and Australia. North Star, its US steelmaking business, is the main contributor, benefiting from wider steel spreads and higher despatch volumes following a project to increase production capacity.

Buildings and Coated Products North America is also expected to improve, supported by stronger volumes and realised prices. Meanwhile, Australian Steel Products is forecast to deliver earnings approaching double those recorded in the second half of FY2026, helped by resilient domestic demand and better sales margins.

The breadth of the improvement matters. Rather than relying on one operation alone, BlueScope is seeing better conditions across several businesses. However, North Star remains the critical earnings driver, making the group sensitive to changes in US steel prices, production costs and demand.

What stands out to us

BlueScope's competitive advantage lies in its established manufacturing assets, customer relationships, distribution networks and branded products, including COLORBOND and ZINCALUME. These are difficult to replicate quickly and provide a stronger position than competing solely on commodity steel prices.

Its North Star operation is particularly important because its earnings can benefit significantly when US steel spreads widen. The recent capacity improvements also offer the potential to generate additional output without requiring an entirely new steelmaking facility.

However, we would not extrapolate the latest earnings upgrade indefinitely. Steel is a cyclical business, and favourable spreads can narrow as supply increases or demand weakens. BlueScope's FY2026 results illustrate this variability: North American operations generated $1.03 billion in underlying EBIT, while Australian Steel Products contributed $188 million.

At approximately $14.2 billion in market capitalisation, the shares also require careful valuation. Compared with FY2026 underlying net profit of $851.2 million, the equity trades at roughly 16.7 times earnings. That multiple is not obviously cheap for a cyclical steelmaker, particularly if current margins prove temporary. Conversely, sustained higher earnings could make the valuation more attractive on a forward basis.

What the company is doing now

BlueScope has been investing to strengthen production capacity and improve operational efficiency, including the North Star debottlenecking project. It is also advancing major Australian manufacturing projects and focusing on higher-value coated and painted steel products.

These initiatives aim to improve volumes, product mix and returns from existing assets. The challenge is ensuring that the additional production translates into sustainable free cash flow after capital expenditure, maintenance and other operating costs.

Investor Insight: Can BlueScope sustain its earnings momentum?

We view BlueScope's guidance upgrade as a meaningful positive because it demonstrates the earnings potential of its established North American assets and improving Australian operations. Its manufacturing scale and branded products provide genuine competitive advantages, but its profitability remains exposed to steel-market cycles. The investment case therefore depends less on whether earnings can reach $1.1 billion in the first half and more on how much of that performance can be sustained. We would become more constructive if subsequent results confirm strong cash generation through changing market conditions.

What happens next?

BlueScope's annual general meeting on 16 November 2026 should provide an opportunity for management to discuss operating conditions and the outlook for the second half.

Investors should focus on realised steel spreads at North Star, Australian sales volumes, operating costs and cash conversion. The first-half result will be important, but the more revealing test will be whether stronger earnings translate into sustainable cash generation and support the company's planned shareholder returns of $3 per share in FY2027.

Alison Elzayed

Alison Elzayed

(Business & Finance Writer | StockScope)

Alison Elzayed is an experienced business and financial writer with more than 10 years of experience in the publishing industry, having previously worked as an author with Bloomsbury Publishing, specialising in business and finance. Throughout her career, Alison has developed a strong understanding of financial markets, corporate developments, economic trends and investment-related topics. Her background in financial publishing has equipped her with the ability to research complex subjects and communicate them in a clear, accurate and engaging manner.

DisclaimerInformation on Stockscope is general in nature and does not constitute financial product advice. It does not take into account your personal objectives, financial situation or needs. Seek independent advice from a qualified financial adviser before making an investment decision. Stockscope and its affiliates do not guarantee the accuracy or completeness of information published on this website. To the extent permitted by law, they accept no liability for any claim, loss or damage arising from its use or reliance on it. Stockscope and its associates may have commercial relationships with companies featured on this website, hold securities in those companies, or receive commissions in connection with capital raisings.

Continue Reading

ASX Weathers Wall Street's AI Rout, but Three Market Risks Are Becoming Harder to Ignore
Market Briefings
Market Briefings

ASX Weathers Wall Street's AI Rout, but Three Market Risks Are Becoming Harder to Ignore

Australian equities: what moved the ASX 200? Australian shares finished lower on Friday, 6 November, as the technology-led sell-off on Wall Street spread across global markets. The ASX 200...

Mark ElzayedMark Elzayed•
Epiminder (ASX: EPI) Expands FDA Clearance as $65 Million Cash Reserve Faces a Crucial Commercial Test
Biotech & Health
Biotech & Health

Epiminder (ASX: EPI) Expands FDA Clearance as $65 Million Cash Reserve Faces a Crucial Commercial Test

Epiminder Limited ASX: EPI has expanded the US market for its epilepsy monitoring technology following a significant regulatory clearance, strengthening its commercial prospects ahead of a p...

Danny AadDanny Aad•
Asara Resources (ASX: AS1) Hits 38m at 2.1g/t Gold: Could Sogosogoba Unlock Kada's Next Growth Phase?
Mining
Mining

Asara Resources (ASX: AS1) Hits 38m at 2.1g/t Gold: Could Sogosogoba Unlock Kada's Next Growth Phase?

A 38-metre gold intersection grading 2.1 grams per tonne has given Asara Resources Limited ASX: AS1 an encouraging exploration result beyond its established Massan deposit in Guinea. The dis...

Alison ElzayedAlison Elzayed•
Alvo Minerals (ASX: ALV) Expands Rare Earth Discovery Across 6.5km², but Can It Deliver Economic Value?
Mining
Mining

Alvo Minerals (ASX: ALV) Expands Rare Earth Discovery Across 6.5km², but Can It Deliver Economic Value?

Alvo Minerals Limited ASX: ALV has extended rare earth mineralisation approximately 2 kilometres beyond previously tested areas at its Boa Vista prospect in Brazil, strengthening the explora...

Alison ElzayedAlison Elzayed•
Avenira Limited (ASX: AEV) Raises $48.9 Million as Wonarah Phosphate Project Faces Its Biggest Test Yet
Mining
Mining

Avenira Limited (ASX: AEV) Raises $48.9 Million as Wonarah Phosphate Project Faces Its Biggest Test Yet

Avenira Limited ASX: AEV has reached a significant financing milestone, with its $48.9 million rights issue providing fresh capital to advance the Wonarah Phosphate Project in the Northern T...

Alison ElzayedAlison Elzayed•
Mayne Pharma Group (ASX: MYX) Unveils $55.5 Million Sale, but Can Its US Business Deliver Stronger Profits?
Biotech & Health
Biotech & Health

Mayne Pharma Group (ASX: MYX) Unveils $55.5 Million Sale, but Can Its US Business Deliver Stronger Profits?

Mayne Pharma Group Limited ASX: MYX is taking a decisive step towards becoming a US-focused pharmaceutical company, agreeing to sell its international operations for $55.5 million. The tran...

Danny AadDanny Aad•
Loading more stories...